Evaluation of Safety and Immunogenicity of Ad26.Mos4.HIV and CH505 TF chTrimer Combination in Healthy Adults

Abroad (travel likely)RecruitingPHASE1

Conditions

Human Immunodeficiency Virus

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Makerere University Walter Reed Project (MUWRP), Kampala, Uganda
Contact: Study coordinator (Grace Mirembe, MBChB, MMed) · gmirembe@muwrp.org · +256 312 330400
Contact: Study coordinator (Betty Mwesigwa, MBChB, MSc) · bmwesigwa@muwrp.org · +256 312 330400

Study leads

Grace Mirembe, MBChB, MMed
Principal Investigator
Makerere University Walter Reed Project P.O. Box 16524, Kampala, Uganda

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

Human Immunodeficiency Virus (HIV) Infection

Abroad (travel likely)RecruitingPHASE2

Aurora, United States · Atlanta, United States

The Effects of Chiropractic Care on Inflammation and Quality of Life in People Living With HIV

Human Immunodeficiency Virus (HIV)

Abroad (travel likely)Recruiting

Marietta, United States

Improving Access to HIV Testing for Children in Uganda

HIV (Human Immunodeficiency Virus)

Abroad (travel likely)Recruiting

Mbarara, Uganda